Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 16/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4377249 | 0.99 | HRH3 (0.97) | HRH3POLBALDH1A1 | |
| SCHEMBL4382907 | 0.99 | HRH3 (0.97) | HRH3POLBALDH1A1 | |
| SCHEMBL4379142 | 0.99 | HRH3 (0.97) | HRH3POLBALDH1A1 | |
| Hydrochloric Acid SCHEMBL4375554 | 0.99 | HRH3 (1.00) | HRH3POLBKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL4375750 | 0.97 | HRH3 (1.00) | HRH3POLBALDH1A1 | |
| Hydrochloric Acid SCHEMBL4382285 | 0.97 | HRH3 (1.00) | HRH3POLBALDH1A1 | |
| Hydrochloric Acid SCHEMBL4377386 | 0.97 | HRH3 (1.00) | HRH3POLBALDH1A1 | |
| SCHEMBL4377510 | 0.97 | HRH3 (0.97) | HRH3POLBDRD2DRD4DRD3 | |
| SCHEMBL4384399 | 0.96 | HRH3 (0.93) | HRH3POLB | |
| Hydrochloric Acid SCHEMBL4379017 | 0.96 | HRH3 (1.00) | HRH3POLBDRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1421071-B1 | SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-11-18 | — | — | EP | claimed |
| EP-1713780-B1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2012-01-18 | — | — | EP | disclosed |
| US-7897633-B2 | Neuronal disorders such as Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function; alcoholism | PROBIODRUG AG (DE) | 2011-03-01 | — | — | US | disclosed |
| US-7897633-B2 | Neuronal disorders such as Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function; alcoholism | PROBIODRUG AG (DE) | 2011-03-01 | — | — | US | disclosed |
| US-20110009420-A1 | Histamine H3 Receptor Ligands | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110009420-A1 | Histamine H3 Receptor Ligands | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100234397-A1 | ENZYME INHIBITORS | PROBIODRUG AG (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234397-A1 | ENZYME INHIBITORS | PROBIODRUG AG (DE) | 2010-09-16 | — | — | US | disclosed |
| US-7728146-B2 | Enzyme inhibitors | PROBIODRUG AG (DE) | 2010-06-01 | — | — | US | disclosed |
| US-7728146-B2 | Enzyme inhibitors | PROBIODRUG AG (DE) | 2010-06-01 | — | — | US | disclosed |
| US-20080113968-A1 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | US | disclosed |
| US-20080113968-A1 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | US | disclosed |
| US-20080113968-A1 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | US | disclosed |
| US-7304086-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2007-12-04 | — | — | US | disclosed |
| US-7304086-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2007-12-04 | — | — | US | disclosed |
| US-20070244177-A1 | ENZYME INHIBITORS | PROBIODRUG AG (DE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244177-A1 | ENZYME INHIBITORS | PROBIODRUG AG (DE) | 2007-10-18 | — | — | US | disclosed |
| WO-2007116092-A1 | ENZYME INHIBITORS | PROBIODRUG AG (DE) | 2007-10-18 | — | — | WO | disclosed |
| US-7208497-B2 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2007-04-24 | — | — | US | disclosed |
| US-7208497-B2 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2007-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113968-A1 | Substituted piperazines and diazepanes | HRH3, HRH4, HRH1 | HRH3 1/4885POLB 3551/4885KDM4E 1567/4885 |
| US-20070244177-A1 | ENZYME INHIBITORS | ACHE, BACE1, MAOA | HRH3 586/4885POLB 840/4885KDM4E 1761/4885 |
| US-20100234397-A1 | ENZYME INHIBITORS | ACHE, MAOA, BACE1 | HRH3 527/4885POLB 571/4885KDM4E 2205/4885 |
| US-20110009420-A1 | Histamine H3 Receptor Ligands | HRH3, HRH4, HRH2 | HRH3 1/4885POLB 4351/4885KDM4E 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.